Biotech | February 17, 2022
Kato wins USFDA approval for studies in retinal disorder
Resolv ER may remedy leading causes of blindness in adults
Resolv ER may remedy leading causes of blindness in adults
Key takeaways of Q3FY22 quarter & conference call highlights
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Key takeaways of recent quarter & conference call highlights
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
Adds five years of market exclusivity on approval
On track to complete the BLA submission in the first half of 2022
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
